|
February 10, 2012
|
| 08:37 EDT |  | AZN |
|
|
February 8, 2012
|
| 09:01 EDT |  | AZN |
|
|
February 7, 2012
|
| 07:20 EDT |  | AZN |
| theflyonthewall.com: | AstraZeneca downgraded to Underperform from Neutral at BofA/Merrill | | BofA/Merrll downgraded AstraZeneca citing weak fundamentals. Price target lowered to $49.20 from $50.70. :theflyonthewall.com |
|
|
February 2, 2012
|
| 16:50 EDT |  | AZN |
|
| 12:18 EDT |  | AZN |
|
| 05:47 EDT |  | AZN |
|
| 05:45 EDT |  | AZN |
|
| 05:45 EDT |  | AZN |
| theflyonthewall.com: | AstraZeneca recommends 10% annual dividend increase to $2.80 | | AstraZeneca said its board has recommended a 5% increase in the second interim dividend to $1.95 to be paid on March 19. This brings the full year dividend to $2.80, an increase of 10%. :theflyonthewall.com |
|
| 05:44 EDT |  | AZN |
|
| 05:41 EDT |  | AZN |
| theflyonthewall.com: | AstraZeneca reports Q4 core EPS $1.61 vs. consensus $1.56 | | Reports Q4 revenue $8.67B vs. consensus $8.59B. :theflyonthewall.com |
|
| 05:40 EDT |  | AZN |
|
|
January 30, 2012
|
| 15:51 EDT |  | AZN |
|
| 07:29 EDT |  | AZN |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com |
|
| 06:12 EDT |  | AZN |
| theflyonthewall.com: | AstraZeneca may announce $3B extension to repurchase program, Independent says |
Subscribe for More Information :theflyonthewall.com |
|